Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical development of ND081 Kaken…
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress…
deCODE genetics/Amgen: New Study Explores the Role of BMI in Disease Risk
REYKJAVIK, Iceland, Nov. 12, 2024 /PRNewswire/ -- New study from deCODE genetics/Amgen highlights…
